Jul. 3 at 6:45 AM
$BLGO Those who truly dig into the details will see what’s unfolding beneath the surface. The recently signed Clyra distribution deal with a powerhouse partner is a game-changer, poised to multiply the success we’ve already seen with Pooph. This isn’t just incremental growth; it’s the kind of catalyst that can redefine BioLargo’s trajectory.
While the broader market remains hesitant, that skepticism is exactly what creates this rare window of opportunity. The disconnect between perception and reality is glaring—and those who recognize it early are positioning themselves for outsized gains.
In fact, I’ve heard from a well-known, deep-pocketed investor with a big following who’s actively accumulating a significant stake—targeting a 5-10 million shares position —before the company’s breakout becomes obvious to the masses. The writing is on the wall: we’re talking months, not years, before BioLargo’s commercial success is undeniable.
This is the moment where conviction pays off.
